Medeze Group Public Company Limited (SET: MEDEZE) has announced that Medeze Treasury Pte. Ltd. (MT), a subsidiary of MEDEZE, has concluded its voluntary conditional cash partial offer to acquire shares in Cordlife Group Limited.
Initially, Medeze Treasury Pte. Ltd. proposed to purchase 25,630,774 shares, representing 10 percent of Cordlife’s total issued shares, at a price of SGD 0.25 per share, with the total transaction value estimated at approximately Baht 165 million.
However, the offer did not meet its conditions. As of 25 June 2025, the partial tender offer resulted in only 694,591 shares being tendered, which is 0.27 percent of the total—failing to satisfy the pre-set conditions.
MT’s financial advisor, PrimePartners Corporate Finance Pte. Ltd. (Singapore), advised that if MT wished to proceed, the purchase price would need to be increased to SGD 0.35 per share, reflecting Cordlife’s market price of SGD 0.33 per share on that date. Alternatively, the advisor stated that MT could terminate the offer at the original SGD 0.25 per share.
After considering these comments and Cordlife Group Limited’s financial information—particularly the delayed submission of its Q1/2025 financial statements—Medeze Treasury Pte. Ltd. maintained that the original offer price of SGD 0.25 per share remained appropriate.
Consequently, MT decided to terminate the partial offer at the initial price. Despite the conclusion of this offer, Cordlife Group Limited and Medeze Group Public Company Limited may continue to discuss potential business opportunities and future collaboration in providing joint services.
About Cordlife Group
Cordlife Group Limited (“Cordlife”, together with its subsidiaries, the “Group”), founded in 2001, owns and operates Asia’s largest network of private cord blood banks. The Group is committed to ensuring the health and well-being of both mother and child, amongst others. Listed on the Mainboard of the Singapore Exchange since 2012, the Group is a pioneer in private cord blood banking in Asia with extensive transplant experience, having processed and stored more than 400,000 cord blood, cord lining, cord tissue, and placenta stem cell samples.
Cordlife is an industry leader in Hong Kong, Indonesia, and the Philippines and one of the top three market leaders in India and Malaysia. Through its majority-owned subsidiary in Malaysia, Stemlife Berhad, Cordlife has an indirect stake in Thailand’s largest private cord blood bank, Thai Stemlife. In addition to cord blood, cord lining, cord tissue, and placenta banking, Cordlife offers families a comprehensive suite of clinical diagnostics, including non-invasive prenatal testing, paediatric vision screening, and newborn metabolic screening. Cordlife strives to ensure reliable quality and is committed to a customer-centric approach.
